SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-021930
Filing Date
2020-05-06
Accepted
2020-05-06 16:11:01
Documents
13
Period of Report
2020-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atra-8k_20200506.htm   iXBRL 8-K 39545
2 EX-99.1 atra-ex991_6.htm EX-99.1 225570
  Complete submission text file 0001564590-20-021930.txt   412170

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20200506.xsd EX-101.SCH 5776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20200506_lab.xml EX-101.LAB 19495
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20200506_pre.xml EX-101.PRE 11632
12 EXTRACTED XBRL INSTANCE DOCUMENT atra-8k_20200506_htm.xml XML 3574
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 20852714
SIC: 2836 Biological Products, (No Diagnostic Substances)